Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
September 26, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October ...
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 23, 2019 16:06 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
August 08, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Top-line Phase 2 refractory status epilepticus (RSE) data on-track for Q3 2019 Scott Braunstein, MD appointed as CEO Nicole Vitullo appointed as Chairman of the Board RADNOR, Pa., Aug. 08, 2019 ...
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
July 23, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Second proof-of-concept study for IV ganaxolone with clinically meaningful activity Ganaxolone IV and oral formulations were safe and well-tolerated Future development in severe depressive disorders...
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
June 19, 2019 16:00 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., June 19, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
June 03, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., June 03, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
May 01, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
March 11, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
March 06, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
March 05, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 05, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...